Sudewi Mukaromah Khoirunnisa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sudewi Mukaromah Khoirunnisa has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Fithria Dyah Ayu Suryanegara
Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands
4 shared publicationsMaarten Jacobus Postma
Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands
4 shared publicationsDidik Setiawan
Faculty of Pharmacy, Universitas Muhammadiyah Purwokerto, Banyumas, Indonesia; Centre for Health Economic Studies, Universitas Muhammadiyah Purwokerto, Banyumas, Indonesia
3 shared publications- Didik Setiawan
Universitas Muhammadiyah Purwokerto, Purwokerto, Indonesia
3 shared publications - Firas Farisi Alkaff
University Medical Center Groningen
1 shared publication - Jurjen van der Schans
Unit of Global Health, Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by Indonesian Young Scientist Group in Pharmacy Reports
- Vol. 6 (1)
Cost of illness of breast cancer in Indonesia in 2024: an analysis from the payer perspective
Breast cancer imposes a substantial clinical and economic burden in Indonesia, particularly within the National Health Insurance system administered by BPJS Kesehatan. Understanding cost variation by disease severity and care type is therefore essential for efficient resource allocation. This retrospective observational study used BPJS Kesehatan claims data to estimate annual direct medical costs from the payer perspective, categorizing expenses into chemotherapy, radiotherapy, surgery, diagnostic procedures, and follow-up examinations. Costs were analyzed by outpatient versus inpatient care and inpatient severity levels (mild, moderate, severe). The total annual direct medical cost reached IDR 834.11 billion. Outpatient care accounted for the largest share of total expenditure, while inpatient care incurred substantially higher per-patient costs. Costs increased consistently with severity across all components, with chemotherapy, surgery, and radiotherapy identified as the main cost drivers, particularly in severe inpatient cases. Median cost differences between outpatient care and all inpatient severity levels were statistically significant (p<0.001). These findings highlight the significant financial burden of breast cancer on Indonesia’s national health insurance system, strongly influenced by disease severity and inpatient utilization, and underscore the importance of early detection and optimized outpatient care to improve efficiency and long-term sustainability of cancer care financing under Indonesia’s national health insurance system (JKN).
- 1 May 2026
- Published by Indonesian Young Scientist Group in Pharmacy Reports
- Vol. 6 (1)
Open AccessCost of illness of breast cancer in Indonesia in 2024: an analysis from the payer perspective
Breast cancer imposes a substantial clinical and economic burden in Indonesia, particularly within the National Health Insurance system administered by BPJS Kesehatan. Understanding cost variation by disease severity and care type is therefore essential for efficient resource allocation. This retrospective observational study used BPJS Kesehatan claims data to estimate annual direct medical costs from the payer perspective, categorizing expenses into chemotherapy, radiotherapy, surgery, diagnostic procedures, and follow-up examinations. Costs were analyzed by outpatient versus inpatient care and inpatient severity levels (mild, moderate, severe). The total annual direct medical cost reached IDR 834.11 billion. Outpatient care accounted for the largest share of total expenditure, while inpatient care incurred substantially higher per-patient costs. Costs increased consistently with severity across all components, with chemotherapy, surgery, and radiotherapy identified as the main cost drivers, particularly in severe inpatient cases. Median cost differences between outpatient care and all inpatient severity levels were statistically significant (p<0.001). These findings highlight the significant financial burden of breast cancer on Indonesia’s national health insurance system, strongly influenced by disease severity and inpatient utilization, and underscore the importance of early detection and optimized outpatient care to improve efficiency and long-term sustainability of cancer care financing under Indonesia’s national health insurance system (JKN).
- Open Access
- 4 February 2026
- Published by Wiley in Tropical Medicine & International Health
- Vol. 31 (4) , 409-421
Where Are the Gaps in Diabetes Care? An Evidence Gap Mapping of the Diabetes Patient Journey in Indonesia
Objective: Understanding the diabetes patient journey, from awareness, screening, diagnosis, treatment, adherence and control, is crucial for improving outcomes. However, in many low‐ and middle‐income countries, including Indonesia, data across this continuum of care remain limited due to limited health information exchange capacity. This study aimed to map and estimate the prevalence of true diabetes and key touchpoints along the patient journey to identify gaps in diabetes management in Indonesia. Methods: We applied an evidence gap mapping approach by systematically searching relevant literature published between 1 January 2014, and 27 March 2025, in PubMed, Web of Science, Scopus and Embase, complemented by unstructured searches of government websites. Evidence was visualised using a chord diagram, bar chart and heatmaps. Random‐effects meta‐analyses were used to estimate pooled prevalence, stratified by study setting and sample representativeness relative to the national population. Results: Among 94 records, none fully applied diabetes patient journey frameworks and most of the evidence was assessed as low quality. Screening was the least studied touchpoint and awareness missed nationally representative data. Pooled prevalence estimates were: true diabetes 13% (95% confidence interval (CI): 9%–17%), awareness 71% (95% CI: 54%–85%), screening 19% (95% CI: 0%–55%), diagnosis 15% (95% CI: 6%–27%), treatment 89% (95% CI: 80%–95%), adherence 59% (95% CI: 49%–69%) and control 31% (95% CI: 25%–36%). Prevalence rates were generally lower in studies conducted in the general population using nationally representative samples. Pooled prevalence across touchpoints and subgroups decreased after excluding low‐quality studies, although heterogeneity within subgroups remained high. Conclusion: Evidence gap mapping offers a practical approach to generating local patient journey data in countries with limited health information exchange capacity. Specifically for Indonesia, a comprehensive consideration of the diabetes patient journey is lacking. Barriers exist across all touchpoints, particularly in the general population.
- 4 February 2026
- Published by Wiley in Tropical Medicine & International Health
- Vol. 31 (4) , 409-421
Open AccessWhere Are the Gaps in Diabetes Care? An Evidence Gap Mapping of the Diabetes Patient Journey in Indonesia
Objective: Understanding the diabetes patient journey, from awareness, screening, diagnosis, treatment, adherence and control, is crucial for improving outcomes. However, in many low‐ and middle‐income countries, including Indonesia, data across this continuum of care remain limited due to limited health information exchange capacity. This study aimed to map and estimate the prevalence of true diabetes and key touchpoints along the patient journey to identify gaps in diabetes management in Indonesia. Methods: We applied an evidence gap mapping approach by systematically searching relevant literature published between 1 January 2014, and 27 March 2025, in PubMed, Web of Science, Scopus and Embase, complemented by unstructured searches of government websites. Evidence was visualised using a chord diagram, bar chart and heatmaps. Random‐effects meta‐analyses were used to estimate pooled prevalence, stratified by study setting and sample representativeness relative to the national population. Results: Among 94 records, none fully applied diabetes patient journey frameworks and most of the evidence was assessed as low quality. Screening was the least studied touchpoint and awareness missed nationally representative data. Pooled prevalence estimates were: true diabetes 13% (95% confidence interval (CI): 9%–17%), awareness 71% (95% CI: 54%–85%), screening 19% (95% CI: 0%–55%), diagnosis 15% (95% CI: 6%–27%), treatment 89% (95% CI: 80%–95%), adherence 59% (95% CI: 49%–69%) and control 31% (95% CI: 25%–36%). Prevalence rates were generally lower in studies conducted in the general population using nationally representative samples. Pooled prevalence across touchpoints and subgroups decreased after excluding low‐quality studies, although heterogeneity within subgroups remained high. Conclusion: Evidence gap mapping offers a practical approach to generating local patient journey data in countries with limited health information exchange capacity. Specifically for Indonesia, a comprehensive consideration of the diabetes patient journey is lacking. Barriers exist across all touchpoints, particularly in the general population.
- Open Access
- 11 September 2025
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 45, 101000
Trends in breast cancer in Indonesia from 2017 to 2020: A national-level analysis by age and disease severity
- 11 September 2025
- Published by Elsevier in Cancer Treatment and Research Communications
- Vol. 45, 101000
Open AccessTrends in breast cancer in Indonesia from 2017 to 2020: A national-level analysis by age and disease severity
- 22 January 2025
- Published by University of Groningen Press
Burden, Challenges, and Future Directions for Breast Cancer Treatment in Indonesia
- 22 January 2025
- Published by University of Groningen Press
Burden, Challenges, and Future Directions for Breast Cancer Treatment in Indonesia
- Open Access
- 24 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0304483
Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis
Background: Trastuzumab has significantly enhanced the survival and prognosis of individuals diagnosed with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Considering its relatively high costs, we aimed to examine the cost-effectiveness of trastuzumab plus chemotherapy compared with chemotherapy alone in HER2-positive early breast cancer from an Indonesian healthcare payer’s perspective. Methods: A Markov model was developed to project the lifetime health benefits and costs associated with trastuzumab treatment for a cohort of women with HER2-positive early breast cancer. Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. Costs were based on verified reimbursement data from Indonesia’s Health and Social Security Agency (BPJS Kesehatan) of the year 2020. A scenario analysis was conducted with efficacy data based on the joint analysis from the NSABP B-31 and NCCTG N9831 trials, allowing for subgroup analysis by age at diagnosis. Univariate and probabilistic sensitivity analyses were conducted to assess the influence of parameter uncertainty. Results: In the base-case analysis, the results indicated that the lifetime costs for trastuzumab plus chemotherapy and chemotherapy alone were US$33,744 and US$22,720, respectively, resulting in substantial incremental savings of US$11,024 per patient for the former. Trastuzumab plus chemotherapy also led to higher total quality-adjusted life years (QALYs) and life years gained (LYG), resulting in incremental cost-effectiveness ratios (ICERs) of US$6,842 per QALY and US$5,510 per LYG. In scenario analysis, the subgroup with an age at diagnosis <40 years old reflected the most cost-effective subgroup. Both the base-case and scenario analyses demonstrated cost-effectiveness with a willingness-to-pay threshold of three-times Gross Domestic Product (GDP). Sensitivity analyses confirmed the robustness of the findings and conclusions. Conclusion: In Indonesia, trastuzumab plus chemotherapy can be considered cost-effective compared to chemotherapy alone at a willingness-to-pay threshold of three times GDP, and it is likely most cost-effective in women <40 years of age.
- 24 May 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (5) , e0304483
Open AccessEconomic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis
Background: Trastuzumab has significantly enhanced the survival and prognosis of individuals diagnosed with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Considering its relatively high costs, we aimed to examine the cost-effectiveness of trastuzumab plus chemotherapy compared with chemotherapy alone in HER2-positive early breast cancer from an Indonesian healthcare payer’s perspective. Methods: A Markov model was developed to project the lifetime health benefits and costs associated with trastuzumab treatment for a cohort of women with HER2-positive early breast cancer. Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. Costs were based on verified reimbursement data from Indonesia’s Health and Social Security Agency (BPJS Kesehatan) of the year 2020. A scenario analysis was conducted with efficacy data based on the joint analysis from the NSABP B-31 and NCCTG N9831 trials, allowing for subgroup analysis by age at diagnosis. Univariate and probabilistic sensitivity analyses were conducted to assess the influence of parameter uncertainty. Results: In the base-case analysis, the results indicated that the lifetime costs for trastuzumab plus chemotherapy and chemotherapy alone were US$33,744 and US$22,720, respectively, resulting in substantial incremental savings of US$11,024 per patient for the former. Trastuzumab plus chemotherapy also led to higher total quality-adjusted life years (QALYs) and life years gained (LYG), resulting in incremental cost-effectiveness ratios (ICERs) of US$6,842 per QALY and US$5,510 per LYG. In scenario analysis, the subgroup with an age at diagnosis <40 years old reflected the most cost-effective subgroup. Both the base-case and scenario analyses demonstrated cost-effectiveness with a willingness-to-pay threshold of three-times Gross Domestic Product (GDP). Sensitivity analyses confirmed the robustness of the findings and conclusions. Conclusion: In Indonesia, trastuzumab plus chemotherapy can be considered cost-effective compared to chemotherapy alone at a willingness-to-pay threshold of three times GDP, and it is likely most cost-effective in women <40 years of age.
- Open Access
- 20 May 2024
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 24 (5) , 613-629
Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review
This study aims to provide a comprehensive assessment of economic and health-related quality of life (HRQoL) outcomes for human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer patients treated with trastuzumab-containing regimens, by focusing on both Incremental Cost-Effectiveness Ratios (ICERs) and quality-adjusted life years (QALYs). A systematic search was conducted across PubMed, Embase, and Scopus databases without language or publication year restrictions. Two independent reviewers screened eligible studies, extracted data, and assessed methodology and reporting quality using the Drummond checklist and Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022), respectively. Costs were converted to US dollars (US$) for 2023 for cross-study comparison. Twenty-two articles, primarily from high-income countries (HICs), were included, with ICERs ranging from US$13,176/QALY to US$254,510/QALY, falling within country-specific cost-effectiveness thresholds. A notable association was observed between higher QALYs and lower ICERs, indicating a favorable cost-effectiveness and health outcome relationship. EQ-5D was the most utilized instrument for assessing health state utility values, with diverse targeted populations. Studies reporting higher QALYs tend to have lower ICERs, indicating a positive relationship between cost-effectiveness and health outcomes. However, challenges such as methodological heterogeneity and transparency in utility valuation persist, underscoring the need for standardized guidelines and collaborative efforts among stakeholders. PROSPERO ID: CRD42021259826.
- 20 May 2024
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 24 (5) , 613-629
Open AccessQuality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review
This study aims to provide a comprehensive assessment of economic and health-related quality of life (HRQoL) outcomes for human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer patients treated with trastuzumab-containing regimens, by focusing on both Incremental Cost-Effectiveness Ratios (ICERs) and quality-adjusted life years (QALYs). A systematic search was conducted across PubMed, Embase, and Scopus databases without language or publication year restrictions. Two independent reviewers screened eligible studies, extracted data, and assessed methodology and reporting quality using the Drummond checklist and Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022), respectively. Costs were converted to US dollars (US$) for 2023 for cross-study comparison. Twenty-two articles, primarily from high-income countries (HICs), were included, with ICERs ranging from US$13,176/QALY to US$254,510/QALY, falling within country-specific cost-effectiveness thresholds. A notable association was observed between higher QALYs and lower ICERs, indicating a favorable cost-effectiveness and health outcome relationship. EQ-5D was the most utilized instrument for assessing health state utility values, with diverse targeted populations. Studies reporting higher QALYs tend to have lower ICERs, indicating a positive relationship between cost-effectiveness and health outcomes. However, challenges such as methodological heterogeneity and transparency in utility valuation persist, underscoring the need for standardized guidelines and collaborative efforts among stakeholders. PROSPERO ID: CRD42021259826.
- Open Access
- 15 March 2024
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 8 (4) , 511-524
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
Background Many trials of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treatment with trastuzumab have provided evidence of improved clinical outcomes. This systematic review examined how a regimen that includes trastuzumab affects patients’ health-related quality of life (HRQoL) during and after treatment. Methods A systematic search for articles published up to February 2023 without restrictions of language or publication year was performed using the Pubmed, Embase, and Scopus databases. We included studies of women aged > 18 years with metastatic HER2-positive breast cancer treated with a trastuzumab-containing regimen. We assessed the quality of the studies using the Cochrane Risk of Bias (RoB) tool (2.0) for randomized controlled trials (RCTs) and the Risk Of Bias In Non-randomised Studies—of Interventions (ROBINS-I) tool for cross-sectional studies. We used Microsoft Excel to extract and synthesize data, and documented the review procedure following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results In total, eight studies compared 1104 trastuzumab-treated patients and 1003 non-trastuzumab-treated patients. Most studies were RCTs (n = 7) and one was a prospective observational study. All the included studies used the EORTC-QLQ-C30, EORTC-QLQ-BR23, FACT-B, or FACT-G questionnaires. During treatment, patients taking regimens that included trastuzumab showed clinical improvement in HRQoL, social functioning, and role functioning. After the treatment, patients’ HRQoL profiles in the trastuzumab and chemotherapy arms were similar. However, trastuzumab (versus chemotherapy) treatment led to clinically improved functional status, role and physical functioning, and fatigue. The quality assessment revealed some concerns in most RCTs, with the risk of bias being high in two studies, low in one study, and moderate in the cross-sectional study. Conclusions Trastuzumab-containing regimens administered to HER2-positive breast cancer patients at the metastatic stage evidenced beneficial effects on total HRQoL during and after treatment. Upon therapy cessation, patients’ HRQoL scores for both interventions improved. Nevertheless, HRQoL profiles of patients treated with trastuzumab were more favorable, particularly for functional status, role functioning, physical well-being, and fatigue. Clinical Trials Registration This review was registered in PROSPERO (registration number: CRD42021259826).
- 15 March 2024
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 8 (4) , 511-524
Open AccessA Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
Background Many trials of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer treatment with trastuzumab have provided evidence of improved clinical outcomes. This systematic review examined how a regimen that includes trastuzumab affects patients’ health-related quality of life (HRQoL) during and after treatment. Methods A systematic search for articles published up to February 2023 without restrictions of language or publication year was performed using the Pubmed, Embase, and Scopus databases. We included studies of women aged > 18 years with metastatic HER2-positive breast cancer treated with a trastuzumab-containing regimen. We assessed the quality of the studies using the Cochrane Risk of Bias (RoB) tool (2.0) for randomized controlled trials (RCTs) and the Risk Of Bias In Non-randomised Studies—of Interventions (ROBINS-I) tool for cross-sectional studies. We used Microsoft Excel to extract and synthesize data, and documented the review procedure following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results In total, eight studies compared 1104 trastuzumab-treated patients and 1003 non-trastuzumab-treated patients. Most studies were RCTs (n = 7) and one was a prospective observational study. All the included studies used the EORTC-QLQ-C30, EORTC-QLQ-BR23, FACT-B, or FACT-G questionnaires. During treatment, patients taking regimens that included trastuzumab showed clinical improvement in HRQoL, social functioning, and role functioning. After the treatment, patients’ HRQoL profiles in the trastuzumab and chemotherapy arms were similar. However, trastuzumab (versus chemotherapy) treatment led to clinically improved functional status, role and physical functioning, and fatigue. The quality assessment revealed some concerns in most RCTs, with the risk of bias being high in two studies, low in one study, and moderate in the cross-sectional study. Conclusions Trastuzumab-containing regimens administered to HER2-positive breast cancer patients at the metastatic stage evidenced beneficial effects on total HRQoL during and after treatment. Upon therapy cessation, patients’ HRQoL scores for both interventions improved. Nevertheless, HRQoL profiles of patients treated with trastuzumab were more favorable, particularly for functional status, role functioning, physical well-being, and fatigue. Clinical Trials Registration This review was registered in PROSPERO (registration number: CRD42021259826).
- Open Access
- 14 April 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis
Background: Despite the benefits of trastuzumab in many trials, evidence of its impact on health-related quality of life (HRQoL) in early treatment has not been summarized. This study explored the effects of trastuzumab treatment on HRQoL, including pooled meta-analysis, in an effort to provide an integrated assessment of HRQoL for Her2-positive early breast cancer patients.Methods: A comprehensive literature review to February 2023 using three databases, focusing on treatment using trastuzumab during the early stage, was performed. The mean changes from baseline during and after treatment were extracted from the included randomized control trials (RCTs) papers and total HRQoL scores were obtained from cross-sectional studies included. Mean difference (MD) and 95% confidence intervals were assessed by a random effect or fixed effect model based on heterogeneity (I2).Results: A total of ten studies were identified and reviewed, consisting of seven RCTs and three cross-sectional studies. The pooled analysis of the mean change from baseline during treatment resulted in an MD of 1.92 (95% CI = 1.59 to 2.25, p < 0.05, I2 = 0%), favoring the trastuzumab group. A non-significant result of the mean change from baseline after treatment appeared in the analysis of 12-month follow-up. In the cross-sectional studies, pooled analyses of HRQoL showed that trastuzumab meaningfully demonstrated an improved HRQoL profile (MD = 9.29, 95% CI = 1.31 to 17.27, p = 0.02, I2 = 0%).Conclusion: Trastuzumab as a targeted therapy resulted in a favorable effect on HRQoL in the early stages of Her2-positive breast cancer. The findings of significant improvements in patients’ HRQoL and less clinically meaningful deterioration in side effects of trastuzumab-containing regimen during treatment were supported by prolonged survival.
- 14 April 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14
Open AccessHealth-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis
Background: Despite the benefits of trastuzumab in many trials, evidence of its impact on health-related quality of life (HRQoL) in early treatment has not been summarized. This study explored the effects of trastuzumab treatment on HRQoL, including pooled meta-analysis, in an effort to provide an integrated assessment of HRQoL for Her2-positive early breast cancer patients.Methods: A comprehensive literature review to February 2023 using three databases, focusing on treatment using trastuzumab during the early stage, was performed. The mean changes from baseline during and after treatment were extracted from the included randomized control trials (RCTs) papers and total HRQoL scores were obtained from cross-sectional studies included. Mean difference (MD) and 95% confidence intervals were assessed by a random effect or fixed effect model based on heterogeneity (I2).Results: A total of ten studies were identified and reviewed, consisting of seven RCTs and three cross-sectional studies. The pooled analysis of the mean change from baseline during treatment resulted in an MD of 1.92 (95% CI = 1.59 to 2.25, p < 0.05, I2 = 0%), favoring the trastuzumab group. A non-significant result of the mean change from baseline after treatment appeared in the analysis of 12-month follow-up. In the cross-sectional studies, pooled analyses of HRQoL showed that trastuzumab meaningfully demonstrated an improved HRQoL profile (MD = 9.29, 95% CI = 1.31 to 17.27, p = 0.02, I2 = 0%).Conclusion: Trastuzumab as a targeted therapy resulted in a favorable effect on HRQoL in the early stages of Her2-positive breast cancer. The findings of significant improvements in patients’ HRQoL and less clinically meaningful deterioration in side effects of trastuzumab-containing regimen during treatment were supported by prolonged survival.